Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Apo B/A1 predicts survival in metastatic renal cell carcinoma

Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

Key clinical point: The ratio of apolipoproteins B and A1 (apo B/A1) was an independent prognostic factor in patients with metastatic renal cell carcinoma (RCC).

Major finding: The preoperative apo B/A1 ratio was independently prognostic for progression-free survival and overall survival, with hazard ratios of 3.131 and 2.173, respectively (P less than .001 for both).

Study details: A retrospective, single-center study including 287 patients with metastatic RCC who underwent cytoreductive nephrectomy.

Disclosures: Beijing Natural Science Foundation supported the study. Dr. Zhang and coauthors had no disclosed conflicts of interest.

Read the article here.


Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010.